메뉴 건너뛰기




Volumn 108, Issue 1, 2009, Pages 211-218

The new food and drug administration drug package insert: Implications for patient safety and clinical care

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTITHROMBOCYTIC AGENT; CHOLINASOL; CIMETIDINE; DIGOXIN; IMDICON; ISOPRENALINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENAZONE; PHENOBARBITAL; PHENYTOIN; PROPRANOLOL DERIVATIVE; SULFANILAMIDE; THEOPHYLLINE; UNCLASSIFIED DRUG;

EID: 58749086751     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e31818c1b27     Document Type: Article
Times cited : (23)

References (35)
  • 1
    • 67549114121 scopus 로고    scopus 로고
    • Kurian GT, Harahan JP. A historical guide to the U.S. government. New York: Oxford University Press, 1998
    • Kurian GT, Harahan JP. A historical guide to the U.S. government. New York: Oxford University Press, 1998
  • 2
    • 0029644362 scopus 로고
    • Elixirs, diluents, and the passage of the 1938 federal food, drug and cosmetic act
    • Wax PM. Elixirs, diluents, and the passage of the 1938 federal food, drug and cosmetic act. Ann Intern Med 1995;122:456-61
    • (1995) Ann Intern Med , vol.122 , pp. 456-461
    • Wax, P.M.1
  • 3
    • 36549038142 scopus 로고    scopus 로고
    • Bolstering the FDA's drug-safety authority
    • Schultz WB. Bolstering the FDA's drug-safety authority. N Engl J Med 2007;357:2217-9
    • (2007) N Engl J Med , vol.357 , pp. 2217-2219
    • Schultz, W.B.1
  • 5
    • 67549103511 scopus 로고    scopus 로고
    • National Biosystems I. Focus Group Report: physician's perceptions of prescription drug labeling information. Focus Group. Plymouth, MN: National Biosystems, Incorporated, 1992. Report No. Contract #223-91-3501
    • National Biosystems I. Focus Group Report: physician's perceptions of prescription drug labeling information. Focus Group. Plymouth, MN: National Biosystems, Incorporated, 1992. Report No. Contract #223-91-3501
  • 6
    • 21744433546 scopus 로고    scopus 로고
    • From the FDA: What's in a label? A guide for the anesthesia practitioner
    • Chang NS, Simone AF, Schultheis LW. From the FDA: what's in a label? A guide for the anesthesia practitioner. Anesthesiology 2005;103:179-85
    • (2005) Anesthesiology , vol.103 , pp. 179-185
    • Chang, N.S.1    Simone, A.F.2    Schultheis, L.W.3
  • 7
    • 0023067716 scopus 로고    scopus 로고
    • LittleJohn JK. Package insert: view of a rural town practitioner. Drug Inf J 1987;21:63-5
    • LittleJohn JK. Package insert: view of a rural town practitioner. Drug Inf J 1987;21:63-5
  • 8
    • 24344465285 scopus 로고    scopus 로고
    • FDA standard: Good enough for government work?
    • Avorn J. FDA standard: good enough for government work? N Engl J Med 2005;353:969-72
    • (2005) N Engl J Med , vol.353 , pp. 969-972
    • Avorn, J.1
  • 10
    • 67549114120 scopus 로고
    • Guidelines for preparing core clinical-safety information on drugs
    • CIOMS Working Group III, Geneva, Switzerland: Council for International Organizations of Medical Sciences
    • CIOMS Working Group III. Guidelines for preparing core clinical-safety information on drugs. Guidelines. Geneva, Switzerland: Council for International Organizations of Medical Sciences, 1995
    • (1995) Guidelines
  • 11
    • 84868981645 scopus 로고    scopus 로고
    • Requirements on content and format of labeling for human prescription drug and biological products. 21 CFR § 201, 314, and 601
    • Requirements on content and format of labeling for human prescription drug and biological products. 21 CFR § 201, 314, and 601
  • 12
    • 33744961171 scopus 로고    scopus 로고
    • Highlights and a hidden hazard-the FDA's new labeling regulations
    • Avorn J, Shrank W. Highlights and a hidden hazard-the FDA's new labeling regulations. N Engl J Med 2006;354:2409-11
    • (2006) N Engl J Med , vol.354 , pp. 2409-2411
    • Avorn, J.1    Shrank, W.2
  • 13
    • 33750338501 scopus 로고    scopus 로고
    • Committee on the assessment of the US drug safety system
    • Institute of Medicine U.S, Baciu A, Stratton KR, Burke SP, eds. Washington, DC: National Academies Press
    • Institute of Medicine (U.S.). Committee on the assessment of the US drug safety system. The future of drug safety: promoting and protecting the health of the public. Baciu A, Stratton KR, Burke SP, eds. Washington, DC: National Academies Press, 2007
    • (2007) The future of drug safety: Promoting and protecting the health of the public
  • 15
    • 33846413998 scopus 로고    scopus 로고
    • The role of litigation in defining drug risks
    • Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA 2007;297:308-11
    • (2007) JAMA , vol.297 , pp. 308-311
    • Kesselheim, A.S.1    Avorn, J.2
  • 16
    • 0031709689 scopus 로고    scopus 로고
    • Black box warnings in prescription drug labeling: Results of a survey of 206 drugs
    • Beach JE, Faich GA, Bormel FG, Sasinowski FJ. Black box warnings in prescription drug labeling: results of a survey of 206 drugs. Food Drug Law J 1998;53:403-11
    • (1998) Food Drug Law J , vol.53 , pp. 403-411
    • Beach, J.E.1    Faich, G.A.2    Bormel, F.G.3    Sasinowski, F.J.4
  • 17
    • 0036972176 scopus 로고    scopus 로고
    • FDA use of the black box warning: Time for reevaluation as a safety tool
    • Liang BA. FDA use of the black box warning: time for reevaluation as a safety tool. J Clin Anesth 2002;14:561-3
    • (2002) J Clin Anesth , vol.14 , pp. 561-563
    • Liang, B.A.1
  • 18
    • 19744377392 scopus 로고    scopus 로고
    • Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron
    • Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005;102:1094-100
    • (2005) Anesthesiology , vol.102 , pp. 1094-1100
    • Charbit, B.1    Albaladejo, P.2    Funck-Brentano, C.3    Legrand, M.4    Samain, E.5    Marty, J.6
  • 19
    • 34748817466 scopus 로고    scopus 로고
    • Droperidol-induced proarrhythmia: The beginning of an answer?
    • Charbit B, Funck-Brentano C. Droperidol-induced proarrhythmia: the beginning of an answer? Anesthesiology 2007; 107:524-6
    • (2007) Anesthesiology , vol.107 , pp. 524-526
    • Charbit, B.1    Funck-Brentano, C.2
  • 21
    • 19744369642 scopus 로고    scopus 로고
    • Effect of low-dose droperidol on the QT interval during and after general anesthesia: A placebo-controlled study
    • White PF, Song D, Abrao J, Klein KW, Navarette B. Effect of low-dose droperidol on the QT interval during and after general anesthesia: a placebo-controlled study. Anesthesiology 2005; 102:1101-5
    • (2005) Anesthesiology , vol.102 , pp. 1101-1105
    • White, P.F.1    Song, D.2    Abrao, J.3    Klein, K.W.4    Navarette, B.5
  • 23
    • 0036395265 scopus 로고    scopus 로고
    • Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs
    • Uhl K, Kennedy DL, Kweder SL. Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs. Drug Saf 2002;25:885-92
    • (2002) Drug Saf , vol.25 , pp. 885-892
    • Uhl, K.1    Kennedy, D.L.2    Kweder, S.L.3
  • 25
    • 0027642031 scopus 로고
    • Perceived readability of warning labels with varied font sizes and styles
    • Silver NC, Braun CC. Perceived readability of warning labels with varied font sizes and styles. Saf Sci 1993;16:615-25
    • (1993) Saf Sci , vol.16 , pp. 615-625
    • Silver, N.C.1    Braun, C.C.2
  • 26
    • 84868981647 scopus 로고    scopus 로고
    • FDA proposes rules for dissemination information on off-label uses. Available at:, Accessed March 5, 2008
    • FDA proposes rules for dissemination information on off-label uses. Available at: www.fda.gov/bbs/topics/NEWS/NEW00643. html. Accessed March 5, 2008
  • 27
    • 0042512222 scopus 로고    scopus 로고
    • Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs
    • O'Reilly J, Dalal A. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs. Ann Health Law 2003;12:295-324
    • (2003) Ann Health Law , vol.12 , pp. 295-324
    • O'Reilly, J.1    Dalal, A.2
  • 28
    • 67549126255 scopus 로고    scopus 로고
    • Sorrel AL. Off-label probes are looking into physicians' role. Amednews Com [serial online], 2006. Available at: http://www.ama-assn.org/amednews/2006/ 08/21/gvsb0821.htm. Accessed March 5, 2008
    • Sorrel AL. Off-label probes are looking into physicians' role. Amednews Com [serial online], 2006. Available at: http://www.ama-assn.org/amednews/2006/ 08/21/gvsb0821.htm. Accessed March 5, 2008
  • 29
    • 84868989266 scopus 로고    scopus 로고
    • is under assault. Available at:, Accessed March 5, 2008
    • The FDA's reputation with the general public is under assault. Available at: http://harrisinteractive.com/news/allnewsbydate. asp?NewsID-1060. Accessed March 5, 2008
    • The FDA's reputation with the general public
  • 30
    • 4344644259 scopus 로고    scopus 로고
    • Scandals have eroded US public's confidence in drug industry
    • Lenzer J. Scandals have eroded US public's confidence in drug industry. BMJ 2004;329:247
    • (2004) BMJ , vol.329 , pp. 247
    • Lenzer, J.1
  • 31
    • 67549111706 scopus 로고    scopus 로고
    • The future of drug safety: promoting and protecting the health of the public, FDA's response to the Institute of Medicine's 2006 report. Available at: http://www.fda.gov/oc/reports/iom013007. html. Accessed March 5, 2008
    • The future of drug safety: promoting and protecting the health of the public, FDA's response to the Institute of Medicine's 2006 report. Available at: http://www.fda.gov/oc/reports/iom013007. html. Accessed March 5, 2008
  • 32
    • 34247871340 scopus 로고    scopus 로고
    • FDA responds to Institute of Medicine drug safety recommendations-in part
    • Psaty BM, Charo RA. FDA responds to Institute of Medicine drug safety recommendations-in part. JAMA 2007;297:1917-20
    • (2007) JAMA , vol.297 , pp. 1917-1920
    • Psaty, B.M.1    Charo, R.A.2
  • 33
    • 61749098380 scopus 로고    scopus 로고
    • The Sentinel Initiative:, Rockville, MD: U.S. Department of Health and Human Services, Office of Critical Path Programs
    • The Sentinel Initiative: National strategy for monitoring medical product safety. Rockville, MD: U.S. Department of Health and Human Services, Office of Critical Path Programs, 2008
    • (2008) National strategy for monitoring medical product safety
  • 34
    • 33646183685 scopus 로고    scopus 로고
    • How the US drug safety system should be changed
    • Strom BL. How the US drug safety system should be changed. JAMA 2006;295:2072-5
    • (2006) JAMA , vol.295 , pp. 2072-2075
    • Strom, B.L.1
  • 35
    • 84868976899 scopus 로고    scopus 로고
    • Available at:, Accessed March, 5, 2008
    • Imdicon. Available at: www.fda.gov/cder/regulatory/physLabel/ Imdicon.pdf. Accessed March, 5, 2008
    • Imdicon


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.